In a recent response to a report prepared by Paul Hunt, former UN Special Rapporteur, the pharmaceutical company GlaxoSmithKline (GSK) has argued that the responsibilities of pharmaceutical companies with respect to the “right to health” is not clearly defined. GSK further comments that its current initiatives, such research and development programmes which target diseases of the developing world, and preferential pricing for low-income countries, do not constitute commitments required by international legal norms. GSK’s response is accessible here. Paul Hunt’s report can be downloaded at http://www.reports-and-materials.org/Paul-Hunt-report-on-GSK-5-May-2009.pdf.
- Update to Blue Marble Health Collection
- Hello, We’re Open
- Simple but elusive – why are we still talking about HIV drug delivery?
- Dismantling gains in global health?
- Lessons and Challenges for Developing and Delivering HIV Programs for Sex Workers
- Advocating for Equitable Access to Global Health Internship Opportunities
TopicsAfrica antimicrobial drugs antiretroviral treatment cardiovascular health child health china clinical trials developing world diarrhea environment ethics Ghostwriting global burden of disease global health guidelines health costs health information health policy health systems HIV HIV/AIDS influenza LMICs malaria maternal and perinatal health maternal health medical literature medical students Mental Health mortality MSF neglected tropical diseases open access pharmaceutical industry Policy public health reporting research ethics sanitation sub-saharan Africa systematic reviews tuberculosis vaccine water WHO